Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Denmark-based NeuroSearch has announced that its development and license partner Abbott has initiated a Phase II study with its diabetic neuropathic pain drug candidate.
Subscribe to our email newsletter
The first patient has been enrolled and dosed in the study. The trial is a randomized, double-blind and placebo-controlled dose-ranging trial to evaluate the efficacy of ABT-894 in patients suffering from diabetic neuropathic pain.
ABT-894 is a subtype selective modulator of neuronal nicotinic acetylcholine receptors (NNR) that has shown promising effects in preclinical models for pain and other central and peripheral nervous system diseases.
Abbott is also conducting a clinical Phase II study with ABT-894 for the treatment of ADHD. The Phase II study in ADHD was initiated in March 2007 and is progressing according to plan.
Under the terms of the license agreement, Abbott is responsible for the clinical development and commercialisation of ABT-894 and will finance all development costs. NeuroSearch will receive milestone payments, as well as royalties on Abbott’s global sales.
The initiation of the Phase II study with ABT-894 in diabetic neuropathic pain does not change NeuroSearch’s financial expectations for 2007 of a loss in the range of DKK230-250 million before recognition of associates and other equity interests as stated in the H1 report 2007 issued on August 22, 2007.